GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...